Healthy Aging & Longevity
CJC-1295 / Ipamorelin
The most widely prescribed growth hormone secretagogue pairing, combining a GHRH analog with a selective ghrelin receptor agonist.
- Physician reviewed
- 503A pharmacy compounded
- Patient-specific prescription
Formats & pricing
- 5mg/5mg vial — reconstituted injectable$320
Pricing reflects the compounded preparation and physician review. Final therapy and dosing are determined only after your intake is reviewed.
Overview
What is CJC-1295 / Ipamorelin?
CJC-1295 is a growth hormone-releasing hormone analog; ipamorelin is a selective growth hormone secretagogue. Together they are used to encourage the body's own pulsatile growth hormone release rather than administering growth hormone directly.
Mechanism
How it works
CJC-1295 extends the GHRH signal to the pituitary, while ipamorelin acts on the ghrelin receptor with comparatively little effect on cortisol or prolactin. The pairing is discussed for producing a more physiologic release pattern.
Wellness support
Potential wellness support areas
These areas are commonly discussed within wellness-focused protocols. They are educational statements, not medical claims or guarantees of outcome.
- Explored for body composition and lean mass
- Discussed for sleep quality and recovery
- Potential support for energy and exercise tolerance
- Commonly monitored with IGF-1 lab work
Administration
Format & dosing
Typically a nightly subcutaneous injection before bed, timed to the body's natural growth hormone pulse. Your physician sets dose and cycle length.
Labs & monitoring
Labs, testing & monitoring
Your physician determines the final testing requirements for CJC-1295 / Ipamorelin after reviewing your intake. The panels below are what is commonly reviewed for this therapy — they are educational guidance, not a fixed requirement.
Bloodwork status
Baseline Labs Generally Required
Commonly reviewed at baseline
- IGF-1
- Comprehensive metabolic panel (CMP)
- Fasting glucose and A1c
- Lipid panel
- Thyroid panel (TSH, free T4)
Follow-up & monitoring
IGF-1, fasting glucose, and A1c are commonly rechecked around 8 to 12 weeks so dosing stays within a physiologic range.
Who may not be a candidate
- Pregnancy or nursing
- Active malignancy without oncology clearance
- Known hypersensitivity to the preparation
- Active proliferative retinopathy
- Uncontrolled diabetes
Medication interactions
Your physician reviews all prescriptions, supplements, and over-the-counter medications during intake before anything is prescribed.
Safety
Safety & considerations
Not FDA-approved; compounded per prescription. Not appropriate with active malignancy. Baseline and follow-up IGF-1 testing is generally recommended.
Regulatory status: Compounded. Evidence level: Moderate. Eligibility, dosing, laboratory requirements, and follow-up care are determined exclusively by a licensed physician after review of your history.
Related therapies
Healthy Aging & Longevity
Tesamorelin
Growth hormone-releasing peptide for visceral fat reduction.
Baseline Labs Generally Required
Healthy Aging & Longevity
Tesamorelin / Ipamorelin
Dual GH secretagogue stack for fat loss and body composition.
Baseline Labs Generally Required
Healthy Aging & Longevity
MOTS-C
Mitochondrial-derived peptide for metabolic health and endurance.
Recent Labs Recommended
Physician reviewed
Every protocol is approved by a licensed physician.
503A compounded
Prepared by licensed US compounding pharmacies.
Patient-specific Rx
Prescriptions are issued in your name only.
No membership
No concierge fee and no subscription to browse or begin.